


FIG. 1**Distribution of IFN transcript scores**

FIG. 2A





FIG. 2B



IFNGS, type I interferon gene signature; n, number of nonmissing values; SE, standard error.

FIG. 3A

Disease activity measure		Placebo (n=66)	Anifrolumab 300 mg (n=84)	Anifrolumab 1000 mg (n=73)
SLEDAI-2K score	Week 52, mean	5.9	4.3	3.8
	Week 60, mean	5.8	5.0	4.1
	Mean change (SD) ^a	-0.1 (2.4)	0.7 (3.5)	0.3 (2.3)
BILAG-2004 score	Week 52, mean	8.3	6.0	5.9
	Week 60, mean	9.1	8.5	6.6
	Mean change (SD) ^a	0.8 (3.8)	2.4 (6.7)	0.7 (5.3)
CLASI activity score	Week 52, mean	3.5 ^b	1.9	1.8
	Week 60, mean	4.0 ^b	2.4	2.2
	Mean change (SD) ^a	0.5 (2.3) ^b	0.4 (1.9)	0.4 (2.0)
MDGA score	Week 52, mean	0.73	0.58	0.65
	Week 60, mean	0.73	0.75	0.73
	Mean change (SD) ^a	0 (0.31)	0.17 (0.54)	0.08 (0.39)
Active joint count	Week 52, mean	2.8 ^b	2.3	1.7
	Week 60, mean	3.2 ^b	3.3	2.4
	Mean change (SD) ^a	0.4 (3.9) ^b	1.0 (4.9)	0.7 (3.5)

FIG. 3B

	Placebo (n=67)	Anifrolumab 300 mg (n=85)	Anifrolumab 1000 mg (n=75)
Patients with ≥ 1 flare, n (%)	2 (3.0)	15 (17.6)	7 (8.2)
Number of flares per patient, n (%)			
0	65 (97.0)	70 (82.4)	68 (90.7)
1	1 (1.5)	14 (16.5)	7 (9.3)
2	1 (1.5)	1 (1.2)	0 (0)
Annualized flare rate per patient, mean (SD)	0.292 (1.771)	1.188 (2.687)	0.585 (1.841)

SD, standard deviation.

FIG 4




FIG. 5

Characteristics	Placebo (n=366)	Anifrolumab 300 mg (n=366)
Age, mean (SD), years	41.0 (11.9)	42.6 (12.0)
Female, n (%)	341 (93.2)	333 (92.5)
Race, n (%)		
White	244 (66.7)	235 (65.3)
Black	35 (9.6)	41 (11.4)
Asian	48 (13.1)	46 (12.8)
Other	31 (8.5)	30 (8.3)
Time from initial SLE diagnosis to randomization, median (range), months	78.5 (4–503)	91.0 (0–555)
BILAG-2004, n (%)		
≥1 A item	179 (48.9)	174 (48.3)
No A items and ≥2 B items	162 (44.3)	170 (47.2)
SLEDAI-2K		
Global score, mean (SD)	11.5 (3.7)	11.4 (3.8)
Score ≥10, n (%)	260 (71.0)	251 (69.7)
PGA score, mean (SD)	1.8 (0.4)	1.8 (0.4)
CLASI activity score, mean (SD)	7.8 (7.2)	8.4 (7.6)
SDI global score, mean (SD)	0.6 (0.9)	0.6 (1.0)
Number of swollen joints, mean (SD)	7.2 (5.7)	6.8 (5.8)
Number of tender joints, mean (SD)	10.8 (7.5)	10.3 (7.4)
Baseline treatment for SLE, n (%)		
OCS ^a	304 (83.1)	291 (80.8)
<10 mg/day	181 (49.5)	351 (48.3)
≥10 mg/day	185 (50.5)	375 (51.7)
Antimalarial	267 (73.0)	243 (67.5)
Immunosuppressant ^b	177 (48.4)	173 (48.1)

FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7




FIG. 8




FIG. 9A




FIG. 9D




FIG. 9B




FIG. 9E




FIG. 9C





FIG. 9F



Data pooled from TULIP-1 and TULIP-2 trials.
Resolution defined as: SLEDAI-2K rash component=0 (patients with SLEDAI-2K rash component=2 at baseline); SLEDAI-2K arthritis component=0 (patients with SLEDAI-2K arthritis component=4 at baseline); Improvement defined as: BILAG rash, mucocutaneous baseline score A change to B, C, or D, or baseline score B change to C or D; BILAG arthritis, musculoskeletal baseline score A change to B, C, or D, or baseline B change to C or D; mCLASI defined as the activity portions of CLASI that describe skin erythema, scale/hypertrophy, and inflammation of the scalp.
BILAG, British Isles Lupus Assessment Group; IFNGS, interferon gene signature; mCLASI, modified Cutaneous Lupus Erythematosus Disease Area and Severity Index; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.

FIG. 10A BILAG-2004




FIG. 10B SLEDAI-2K




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19





FIG. 20






FIG. 21A




FIG. 21B

FIG. 22A




FIG. 22B




FIG. 22C




FIG. 23A




FIG. 23B




FIG. 23C




FIG. 23D




FIG. 24

